Trial Profile
Phase I, Randomized, Double-Blind, Placebo Controlled, Dose Escalation,Single Dose, Safety, Tolerance, and Pharmacokinetic Study of CXB909 in Healthy Male Volunteers.
Status:
Not yet recruiting
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs CXB 909 (Primary)
- Indications Alzheimer's disease; Neurological disorders
- Focus Pharmacokinetics
- 12 Jan 2012 New trial record